To assess the prognostic value of GDF15 expression in primary prostate cancer, we analyzed the Erho microarray dataset, which contains 545 radical prostatectomy samples with a median follow-up of 16.9 years [38], for association with clinicopathologic parameters. The gene discussed is GDF15; the disease is prostate cancer.